| |
| Physical Characters and Index |
Name: 4-benzyl-2 -(naphthalen-1-yl)-[1,2,4]thiadiazolidine-3,5-dione
CAS: 865854-05-3
Molecular formula: C19H14N2O2S
Molecular weight: 334.39
EINECS number: 640-411-8
Melting point :148-150 ° C
Boiling point :511.3±43.0 °C(Predicted)
Density :1.393
Storage :2-8°C
Solubility :DMSO: >15mg/mL |
| |
| Use and description |
| Tideglusib is an orally available, small-molecule drug of the thiadiazolidinone class. It acts as an inhibitor of glycogen synthase kinase 3 (GSK3-β), a widely studied tau kinase. The rationale for its use is that inhibiting GSK3-β will counteract tau hyperphosphorylation, which is thought be a step in the cellular pathogenesis that leads to Alzheimer’s disease and other neurodegenerative diseases marked by neurofibrillary tau pathology. Tideglusib was being developed for the treatment of Alzheimer’s and the tauopathy progressive supranuclear palsy (PSP) as part of a drug-discovery program based on marine-derived GSK3-β inhibitors. |
|
